Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE3.8000
- TODAY'S CHANGE (%)-0.5000 (-11.6279%)
- Bid / Lots3.7600/ 1
- Ask / Lots3.9600/ 4
- Open / Previous Close4.3500 / 4.3000
- Day Range
- 52 Week Range
- Volume628,283
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 16626 | 4.43 |
| 09:33 ET | 1600 | 4.41 |
| 09:37 ET | 1000 | 4.38 |
| 09:42 ET | 23785 | 4.29 |
| 09:44 ET | 200 | 4.3199 |
| 09:46 ET | 200 | 4.29 |
| 09:48 ET | 1000 | 4.3 |
| 09:50 ET | 1010 | 4.28 |
| 09:51 ET | 540 | 4.25 |
| 09:53 ET | 1927 | 4.23 |
| 09:55 ET | 200 | 4.22 |
| 09:57 ET | 300 | 4.21 |
| 10:00 ET | 450 | 4.15 |
| 10:02 ET | 1179 | 4.17 |
| 10:04 ET | 2536 | 4.215 |
| 10:06 ET | 525 | 4.23 |
| 10:09 ET | 530 | 4.23 |
| 10:11 ET | 2581 | 4.24 |
| 10:13 ET | 240 | 4.2141 |
| 10:18 ET | 3700 | 4.16 |
| 10:20 ET | 400 | 4.17 |
| 10:22 ET | 3539 | 4.17 |
| 10:24 ET | 4754 | 4.14 |
| 10:26 ET | 210 | 4.14 |
| 10:27 ET | 5377 | 4.1015 |
| 10:29 ET | 1370 | 4.1 |
| 10:31 ET | 4159 | 4.1 |
| 10:33 ET | 1691 | 4.105 |
| 10:36 ET | 3448 | 4.07 |
| 10:38 ET | 100 | 4.08 |
| 10:40 ET | 2400 | 4.063 |
| 10:42 ET | 1235 | 4.065 |
| 10:45 ET | 500 | 4.07 |
| 10:47 ET | 471 | 4.06 |
| 10:51 ET | 2200 | 4.08 |
| 10:54 ET | 200 | 4.07 |
| 10:56 ET | 2500 | 4.07 |
| 10:58 ET | 700 | 4.07 |
| 11:00 ET | 1222 | 4.08 |
| 11:02 ET | 600 | 4.07 |
| 11:03 ET | 5939 | 4.07 |
| 11:07 ET | 289 | 4.07 |
| 11:09 ET | 192 | 4.07 |
| 11:12 ET | 300 | 4.075 |
| 11:14 ET | 490 | 4.07 |
| 11:18 ET | 500 | 4.09 |
| 11:20 ET | 300 | 4.08 |
| 11:23 ET | 239 | 4.0989 |
| 11:25 ET | 200 | 4.1 |
| 11:27 ET | 100 | 4.105 |
| 11:30 ET | 1511 | 4.11 |
| 11:32 ET | 543 | 4.12 |
| 11:34 ET | 218 | 4.12 |
| 11:36 ET | 200 | 4.12 |
| 11:39 ET | 8028 | 4.09 |
| 11:41 ET | 4166 | 4.11 |
| 11:43 ET | 1003 | 4.12 |
| 11:48 ET | 100 | 4.12 |
| 11:50 ET | 365 | 4.12 |
| 11:52 ET | 900 | 4.11 |
| 11:54 ET | 400 | 4.11 |
| 11:56 ET | 200 | 4.11 |
| 11:57 ET | 1195 | 4.11 |
| 11:59 ET | 100 | 4.11 |
| 12:01 ET | 3584 | 4.13 |
| 12:03 ET | 3462 | 4.105 |
| 12:06 ET | 3500 | 4.12 |
| 12:08 ET | 8805 | 4.12 |
| 12:10 ET | 2300 | 4.12 |
| 12:12 ET | 456 | 4.11 |
| 12:19 ET | 100 | 4.11 |
| 12:24 ET | 823 | 4.09 |
| 12:28 ET | 100 | 4.095 |
| 12:32 ET | 5152 | 4.115 |
| 12:33 ET | 300 | 4.09 |
| 12:35 ET | 11200 | 4.075 |
| 12:37 ET | 1890 | 4.075 |
| 12:39 ET | 400 | 4.08 |
| 12:42 ET | 1029 | 4.095 |
| 12:51 ET | 339 | 4.08 |
| 12:53 ET | 200 | 4.07 |
| 12:55 ET | 946 | 4.08 |
| 12:57 ET | 4030 | 4.07 |
| 01:00 ET | 700 | 4.06 |
| 01:02 ET | 600 | 4.06 |
| 01:04 ET | 1392 | 4.06 |
| 01:08 ET | 6688 | 4.02 |
| 01:09 ET | 100 | 4.035 |
| 01:11 ET | 100 | 4.04 |
| 01:13 ET | 1434 | 4.05 |
| 01:15 ET | 100 | 4.04 |
| 01:20 ET | 694 | 4.06 |
| 01:22 ET | 110029 | 3.961 |
| 01:24 ET | 5416 | 3.98 |
| 01:26 ET | 800 | 3.9899 |
| 01:27 ET | 230 | 3.985 |
| 01:29 ET | 200 | 4.01 |
| 01:31 ET | 222 | 3.98 |
| 01:36 ET | 1568 | 3.99 |
| 01:38 ET | 1637 | 3.995 |
| 01:40 ET | 104 | 3.995 |
| 01:42 ET | 200 | 3.99 |
| 01:44 ET | 3059 | 3.98 |
| 01:47 ET | 100 | 3.99 |
| 01:49 ET | 2667 | 3.9799 |
| 01:51 ET | 500 | 3.96 |
| 01:54 ET | 464 | 3.94 |
| 01:56 ET | 3228 | 3.94 |
| 02:00 ET | 7970 | 3.91 |
| 02:02 ET | 2840 | 3.92 |
| 02:03 ET | 1193 | 3.93 |
| 02:07 ET | 2746 | 3.93 |
| 02:09 ET | 1640 | 3.95 |
| 02:12 ET | 1300 | 3.93 |
| 02:14 ET | 200 | 3.94 |
| 02:16 ET | 6422 | 3.92 |
| 02:18 ET | 1000 | 3.9 |
| 02:21 ET | 123 | 3.906 |
| 02:23 ET | 200 | 3.903 |
| 02:25 ET | 3916 | 3.91 |
| 02:27 ET | 4780 | 3.9 |
| 02:30 ET | 2044 | 3.89 |
| 02:32 ET | 1358 | 3.8807 |
| 02:34 ET | 1700 | 3.88 |
| 02:36 ET | 600 | 3.88 |
| 02:38 ET | 6654 | 3.88 |
| 02:39 ET | 100 | 3.8775 |
| 02:41 ET | 2678 | 3.89 |
| 02:43 ET | 2596 | 3.89 |
| 02:45 ET | 1570 | 3.8929 |
| 03:15 ET | 2525 | 3.8494 |
| 03:17 ET | 200 | 3.845 |
| 03:19 ET | 11262 | 3.815 |
| 03:21 ET | 19684 | 3.835 |
| 03:24 ET | 15088 | 3.815 |
| 03:26 ET | 400 | 3.83 |
| 03:28 ET | 500 | 3.835 |
| 03:30 ET | 1967 | 3.8393 |
| 03:32 ET | 500 | 3.835 |
| 03:33 ET | 1100 | 3.83 |
| 03:35 ET | 1200 | 3.835 |
| 03:37 ET | 300 | 3.835 |
| 03:39 ET | 400 | 3.84 |
| 03:42 ET | 407 | 3.833366 |
| 03:44 ET | 1260 | 3.84 |
| 03:46 ET | 4182 | 3.84 |
| 03:48 ET | 11772 | 3.825 |
| 03:50 ET | 2672 | 3.8201 |
| 03:51 ET | 6596 | 3.805 |
| 03:53 ET | 4517 | 3.79 |
| 03:55 ET | 500 | 3.789 |
| 03:57 ET | 8724 | 3.8 |
| 04:00 ET | 34147 | 3.8 |
Nov 14, 2024
Press Release: Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow JonesCandel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Oct 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 121.9M | -2.2x | --- |
Alto Neuroscience Inc | 121.9M | -1.9x | --- |
Rani Therapeutics Holdings Inc | 121.7M | -2.2x | --- |
InflaRx NV | 114.8M | -1.9x | --- |
Outlook Therapeutics Inc | 128.0M | -0.7x | --- |
Vigil Neuroscience Inc | 130.4M | -1.5x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Chief Medical Officer
- W. Garrett Nichols
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $121.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.95 |
EPS | $-1.70 |
Book Value | $0.44 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
